[
    "lture (MICs as low as \u02dc0.3 \u03bcg/ml).</p>The applicants have shown, through the isolation, sequencing, and characterization of resistant mutants of Mycobacterium smegmatis, that compounds of general structural formulae (I), (II), (III), and (IV) function through a site on RNA polymerase located at the base of the RNA polymerase \u201c\u03b2 lobe.\u201d</p>The applicants have shown, through the isolation, sequencing, and characterization of resistant mutants of Mycobacterium smegmatis, that compounds of general structural formulae (I), (II), (III), and (IV) function through a site on RNA polymerase that is different from, and does not overlap, the binding sites for the prior-art RNA polymerase inhibitors rifampin, myxopyronin, and lipiarmycin.</p>The applicants have shown that compounds of general structural formulae (I), (II), (III), and (IV) do not exhibit target-based cross-resistance with the prior-art RNA polymerase inhibitors rifampin, myxopyronin, and lipiarmycin.</p>The applicants have demonstrated that they are able to discover new compositions of matter according to general structural formulae (I), (II), (III), and (IV) that inhibit a bacterial RNA polymerase or that inhibit one of the growth of a bacterium and the viability of a bacterium. For example, the applicants have discovered that N\u03b1-phenyl-N-(2-pyridyl)-phenylalaninamide, a new composition of matter according to general structural formula (I), (II), (III), or (IV), inhibits Mycobacterium tuberculosis RNA polymerase in vitro (IC50 \u02dc1 \u03bcM) and inhibits the growth of Mycobacterium smegmatis in culture (MIC \u02dc3 \u03bcg/ml).</p>Certain embodiments of the invention provide for use of an N\u03b1-aroyl-N-aryl-phenylalaninamide to inhibit an RNA polymerase from a bacterium or to inhibit growth or viability of a bacterium.</p>In certain embodiments, the invention provides for use of an N\u03b1-aroyl-N-aryl-phenylalaninamide to inhibit an RNA polymerase from a mycobacterium or to inhibit growth of viability of a mycobacterium. </p>In certain embodiments, the invention provides for use of an N\u03b1-aroyl-N-aryl-phenylalaninamide to inhibit RNA polymerase from one of Mycobacterium tuberculosis, Mycobacterium bovis, Mycobacterium leprae, Mycobacterium avium, and Mycobacterium smegmatis or to inhibit growth or viability of Mycobacterium tuberculosis, Mycobacterium bovis, Mycobacterium leprae, Mycobacterium avium, and Mycobacterium smegmatis. </p>The invention has applications, e.g., in antibacterial prophylaxis, antibacterial therapy, and drug discovery.</p>Compounds of general structural formulae (I), (II), (III), and (IV) have utility as inhibitors of a bacterial RNA polymerase, as antibacterial agents, as antimycobacterial agents and as antituberculosis agents.</p>In particular, the applicants disclose herein that compounds of general structural formula (V) or (VI) highly potently inhibit mycobacterial RNA polymerase in vitro and inhibit one of the growth and the viability of a mycobacterium in culture. For example, the applican",
    "60347708A1-20161201-C00004.TIF\" file=\"https://surechembl.org/api/assets/attachment/362997790/US/20161201/A1/020160/34/77/08/US20160347708A1-20161201-C00004.TIF\"/></p>where X\u2032\u2033, Y\u2032\u2033, and Z\u2032\u2033 each independently is one of phenyl, pyridyl, pyrazinyl, furyl, thiophenyl, pyrrolyl, oxazoyl, thioxazoyl, isoxazoyl, thioisoxazoyl, napthyl, benzofuranyl, benzothiofuranyl, or indoyl, each optionally substituted with C1-C5 acyl, C1-C5-O-acyl, C1-C5-NH-acyl, carboxy, C1-C5 ester, C1-C5 amide, C1-C5 alkoxy, C1-C5-monoalkylamino, C1-C5 dialkylamino, amino, hydroxy, or halogen; and\n\nwhere the configuration of the C\u03b1 atom of the amino acid moiety containing Y is D.\n</p>In certain embodiments, where X\u2032\u2033 is unsubstituted 2-thiophenyl and Y\u2032\u2033 is unsubstituted phenyl, Z\u2032\u2033 is not 2-morpholino-phenyl.</p>In certain embodiments, where X\u2032\u2033 is unsubstituted 2-thiophenyl and Y\u2032\u2033 is unsubstituted phenyl, Z\u2032\u2033 is not 2-ethoxy-phenyl.</p>In certain embodiments, where X\u2032\u2033 and Y\u2032\u2033 are unsubstituted phenyl, Z\u2032\u2033 is not 2-methyl-phenyl.</p>In certain embodiments, where where X\u2032\u2033 and Y\u2032\u2033 are unsubstituted phenyl, Z\u2032\u2033 is not 4-methyl-phenyl.</p>In certain embodiments, where X\u2032\u2033 is unsubstituted 2-furyl and Y\u2032\u2033 is unsubstituted phenyl, Z\u2032\u2033 is not 4-acetyl-phenyl.</p>In certain embodiments, where X\u2032\u2033 is unsubstituted 2-furyl and Y\u2032\u2033 is unsubstituted phenyl, Z\u2032\u2033 is not 4-methyl-phenyl.</p>In certain embodiments, the compound according to general structural formula (I), (II), (III), or (IV), or a salt thereof, has an IC50 of less than about 25 micromolar for inhibiting an RNA polymerase from a bacterium.</p>In certain embodiments, the compound according to general structural formula (I), (II), (III), or (IV) is</p><img id=\"EMI-C00005\" path=\"US20160347708A1-20161201-C00005.TIF\" file=\"https://surechembl.org/api/assets/attachment/362997798/US/20161201/A1/020160/34/77/08/US20160347708A1-20161201-C00005.TIF\"/><img id=\"EMI-C00006\" path=\"US20160347708A1-20161201-C00006.TIF\" file=\"https://surechembl.org/api/assets/attachment/362996076/US/20161201/A1/020160/34/77/08/US20160347708A1-20161201-C00006.TIF\"/></p>Certain embodiments of the invention provide the use of a compound according to general structural formula (I), (II), (III), or (IV), or a salt thereof, to inhibit an RNA polymerase from a mycobacterium. </p>Certain embodiments of the invention provide the use of a compound according to general structural formula (I), (II), (III), or (IV), or a salt thereof, to inhibit an RNA polymerase from one of Mycobacterium tuberculosis, Mycobacterium bovis, Mycobacterium leprae, Mycobacterium avium, and Mycobacterium smegmatis. </p>Certain embodiments of the invention provide the use of a compound according to general structural formula (I), (II), (III), or (IV), or a salt thereof, to inhibit the growth and/or the viability of a bacterium.</p>Certain embodiments of the invention provide the use of a compound according to general structural formula (I), (II), (III), or (IV), or a salt thereof, to inhibit t",
    " stirring was continued for 2 h. The mixture was filtered through a plug of glass wool and evaporated to dryness. The sample was re-dissolved in chloroform and purified by silica chromatography (methanol gradient in chloroform).</p>Yield: 10 mg, 29%. MS (MALDI): calculated: m/z 345.39 (MH<sup>+</sup>). found: 367.35 (M+Na<sup>+</sup>).</p>Example 8Assay of Inhibition of Mycobacterial RNA PolymeraseRun-off transcription assays with Mycobacterium tuberculosis RNA polymerase were performed using reaction mixtures containing (10 \u03bcl): 0-100 \u03bcM test compound, 75 nM Mycobacterium tuberculosis RNA polymerase core enzyme, 300 nM Mycobacterium tuberculosis \u03c3<sup>A</sup>, 20 nM 130 bp DNA fragment containing positions \u2212100 to \u22121 of the bacteriophage T4 N25 promoter followed by positions +1 to +30 of the lacUV5-15 promoter of [Mukhopadhyay, J., Kapanidis, A., Mekler, V., Kortkhonjia, E., Ebright, Y., Ebright, R. (2001) Cell 106, 453-463], 25 nM [alpha-<sup>32</sup>P]UTP (600 Bq/pmol) for an initial 2 min at 37\u00b0 C. and 100 \u03bcM [alpha-<sup>32</sup>P]UTP (6 Bq/pmol) for a subsequent 5 min at 37\u00b0 C., 100 \u03bcM ATP, 100 \u03bcM GTP, 100 \u03bcM UTP, 100 \u03bcM CTP, 40 mM Tris-HCl, pH 8.0, 80 mM NaCl, 5 mM MgCl<sub>2</sub>, 2.5 mM DTT, and 12.7% glycerol. Reactions were terminated by addition of 2 l 80% formamide, 10 mM EDTA, 0.04% bromophenol blue, and 0.04% xylene cyanol, followed by heating for 5 min at 90\u00b0 C. Reaction products were resolved by 15% urea-PAGE, and quantified using a storage-phosphor scanner. IC50 was defined as the concentration of inhibitor resulting in 50% inhibition of RNA polymerase activity.</p>Certain compounds according to the general structural formulae were found to potently inhibit mycobacterial RNA polymerase (IC50s=0.01 to 12 \u03bcM; Tables 1, 9).</p>In particular, certain compounds according to general structural formula (V) or VI) were found to highly potently inhibit mycobacterial RNA polymerase (IC50s=0.01 to 3.5 \u03bcM; Tables 9, 10).</p>For the series AAP1 (DL racemic mixture), AAP1a (D stereoisomer), and AAP1b (L stereoisomer), the D stereoisomer inhibited mycobacterial RNA polymerase more potently that the DL racemic mixture, and the DL racemic mixture inhibited mycobacterial RNA polymerase more potently than the L stereoisomer (Table 1).</p>Similarly, for the series IX-214 (DL racemic mixture) and IX-214a (D stereoisomer), the D stereoisomer inhibited mycobacterial RNA polymerase more potently than the DL racemic mixture (Tables 9, 10).</p>Similarly, for the series IX-274 (DL racemic mixture) and IX-274a (D stereoisomer), the D stereoisomer inhibited mycobacterial RNA polymerase more potently than the DL racemic mixture (Tables 9, 10).</p>By comparison to their potent inhibition of mycobacterial RNA polymerase polymerase (IC50s as low as 0.01 \u03bcM; Tables 1, 9, 10), tested compounds according to the general structural formulae less potently inhibited Escherichia coli RNA polymerase in analogous run-off transcription assays with Escherichia coli RNA pol"
]